Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.49
-0.09 (-1.19%)
Apr 29, 2025, 12:45 PM EDT - Market open
Journey Medical Revenue
In the year 2024, Journey Medical had annual revenue of $56.13M, down -29.11%. Journey Medical had revenue of $13.62M in the quarter ending December 31, 2024, a decrease of -10.73%.
Revenue (ttm)
$56.13M
Revenue Growth
-29.11%
P/S Ratio
2.76
Revenue / Employee
$1,369,122
Employees
41
Market Cap
173.05M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
DERM News
- 22 days ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 27 days ago - Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea - GlobeNewsWire